IL270460A - - Google Patents
Info
- Publication number
- IL270460A IL270460A IL27046019A IL27046019A IL270460A IL 270460 A IL270460 A IL 270460A IL 27046019 A IL27046019 A IL 27046019A IL 27046019 A IL27046019 A IL 27046019A IL 270460 A IL270460 A IL 270460A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705686.2A GB201705686D0 (en) | 2017-04-07 | 2017-04-07 | Novel compounds and therapeutic uses thereof |
| PCT/GB2018/050928 WO2018185495A1 (en) | 2017-04-07 | 2018-04-06 | Novel compounds and therapeutic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270460A true IL270460A (enExample) | 2019-12-31 |
| IL270460B1 IL270460B1 (en) | 2023-05-01 |
| IL270460B2 IL270460B2 (en) | 2023-09-01 |
Family
ID=58744828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270460A IL270460B2 (en) | 2017-04-07 | 2018-04-08 | New compounds and their medicinal uses |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11766483B2 (enExample) |
| EP (1) | EP3606561B1 (enExample) |
| JP (2) | JP7695773B2 (enExample) |
| KR (1) | KR102646581B1 (enExample) |
| CN (1) | CN110753558B (enExample) |
| AU (1) | AU2018248706B2 (enExample) |
| CA (1) | CA3059018A1 (enExample) |
| ES (1) | ES2954294T3 (enExample) |
| GB (1) | GB201705686D0 (enExample) |
| IL (1) | IL270460B2 (enExample) |
| WO (1) | WO2018185495A1 (enExample) |
| ZA (1) | ZA201906580B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201816553D0 (en) | 2018-10-10 | 2018-11-28 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| GB202406865D0 (en) | 2024-05-15 | 2024-06-26 | Centauri Therapeutics Ltd | Novel compounds and therapeutics uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090381A (en) * | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| FR2801305B1 (fr) | 1999-11-24 | 2002-12-06 | Galderma Res & Dev | Analogues de la vitamine d |
| US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| FI20011664A7 (fi) | 2001-08-17 | 2003-02-18 | Carbion Oy | Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö |
| EP2322209A3 (en) | 2002-08-20 | 2012-02-01 | Glykos Finland Oy | Tumor specific oligosaccharide epitopes and use thereof |
| EP1882684B1 (en) | 2005-05-19 | 2014-12-10 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
| FR2886298A1 (fr) * | 2005-05-24 | 2006-12-01 | Ifremer | Anticorps ou fragment d'anticorps couple a un agent immunogene |
| CN105709237A (zh) * | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CA2655246A1 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| US9156906B2 (en) | 2008-02-26 | 2015-10-13 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
| EP2283358B1 (en) * | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| US9079880B2 (en) * | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| EP2836485B1 (en) * | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| US9556167B2 (en) | 2012-05-02 | 2017-01-31 | Yale University | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
| US10973920B2 (en) * | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| GB201517859D0 (en) * | 2015-10-08 | 2015-11-25 | Altermune Ltd | Novel compounds and therapeutic uses thereof |
| BR112019004877A2 (pt) * | 2016-09-13 | 2019-06-11 | Centauri Therapeutics Limited | novos compostos e usos terapêuticos dos mesmos |
-
2017
- 2017-04-07 GB GBGB1705686.2A patent/GB201705686D0/en not_active Ceased
-
2018
- 2018-04-06 KR KR1020197032866A patent/KR102646581B1/ko active Active
- 2018-04-06 CN CN201880037436.4A patent/CN110753558B/zh active Active
- 2018-04-06 WO PCT/GB2018/050928 patent/WO2018185495A1/en not_active Ceased
- 2018-04-06 CA CA3059018A patent/CA3059018A1/en active Pending
- 2018-04-06 EP EP18717680.5A patent/EP3606561B1/en active Active
- 2018-04-06 AU AU2018248706A patent/AU2018248706B2/en active Active
- 2018-04-06 ES ES18717680T patent/ES2954294T3/es active Active
- 2018-04-06 US US16/603,579 patent/US11766483B2/en active Active
- 2018-04-06 JP JP2019554924A patent/JP7695773B2/ja active Active
- 2018-04-08 IL IL270460A patent/IL270460B2/en unknown
-
2019
- 2019-10-07 ZA ZA2019/06580A patent/ZA201906580B/en unknown
-
2023
- 2023-04-14 JP JP2023066568A patent/JP2023100679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7695773B2 (ja) | 2025-06-19 |
| WO2018185495A1 (en) | 2018-10-11 |
| CN110753558B (zh) | 2023-10-24 |
| EP3606561C0 (en) | 2023-08-02 |
| IL270460B1 (en) | 2023-05-01 |
| ES2954294T3 (es) | 2023-11-21 |
| US20200147236A1 (en) | 2020-05-14 |
| US11766483B2 (en) | 2023-09-26 |
| AU2018248706A1 (en) | 2019-11-07 |
| ZA201906580B (en) | 2024-01-31 |
| EP3606561A1 (en) | 2020-02-12 |
| KR20200018402A (ko) | 2020-02-19 |
| CN110753558A (zh) | 2020-02-04 |
| AU2018248706B2 (en) | 2022-04-07 |
| GB201705686D0 (en) | 2017-05-24 |
| EP3606561B1 (en) | 2023-08-02 |
| KR102646581B1 (ko) | 2024-03-13 |
| CA3059018A1 (en) | 2018-10-11 |
| JP2023100679A (ja) | 2023-07-19 |
| JP2020516613A (ja) | 2020-06-11 |
| IL270460B2 (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (enExample) | ||
| BR112019008823A2 (enExample) | ||
| BR112020006084A8 (enExample) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020009729B1 (pt) | Inibidores de acss2 e métodos de uso dos mesmos | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112020000320B1 (pt) | Dispositivo bioerodível de administração de fármacos, seu método de preparação, e uso de uma folha não-tecido | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019024244B1 (pt) | Processos de fermentação de metano de alta produtividade | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores |